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Dissertation Abstract 
Background: The prevalence of HIV was greater than 30% in the Free State province 
in South Africa and PMTCT services were widely available at the time the guidelines 
recommended nevirapine in labour and to the child postpartum.  
Aim: The aim was to determine the effectiveness of the PMTCT program in the Free 
State by measuring HIV transmission and HIV-free survival in children less than two 
years of age. Variables associated with HIV transmission and HIV-free survival 
including PMTCT uptake by mother, demographic characteristics, type of delivery and 
breastfeeding status were investigated. 
Methods: This was a secondary analysis of data collected from a cross sectional 
community household survey, using multistage cluster sampling. The population was all 
women who had given birth to a child in the two years prior to the study in the 
catchment area of three sub-districts that were randomly selected in Free State.  All 
mothers were anonymously tested for HIV and if infected the child was also tested. 
Trained field workers interviewed mothers, identified children who had died and 
collected data on variables that could be related to transmission and survival. Logistic 
regression was used to determine risk factors. 
Results: HIV exposure and outcome status was known for 874 (75.50%) of the 1158 
children under 2 years of age who were identified. Ninety seven children (11.10%) were 
exposed to HIV. One exposed (1.03%) and HIV positive child died from an HIV related 
illness. One other exposed but uninfected child (1.03%) died from other causes. Thirty 
(3.86%) unexposed children died. Transmission was 52.63% from mothers who did not 
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receive any form of PMTCT and 11.84% in mothers who received some form of 
PMTCT. There was a 72% reduction in survival in children who had been hospitalised at 
least once since birth while those who were still breastfed at the time of the interview 
were 5.08 times more likely to survive (p=0.001).  Although many studies have shown 
that a number of factors are associated with HIV transmission from mother to child, in 
this study no variables were significantly associated with transmission in the adjusted 
multivariate analysis, besides a child being hospitalized at least once since birth 
(p<0.001).  
Conclusion: Breast feeding and being admitted to hospital at least once since birth 
were significantly associated with survival and further research is recommended on the 
impact of these factors on transmission and survival. .  
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Measuring PMTCT effectiveness through HIV free survival in children under 2 
years 
Protocol summary 
Evaluation of the operational effectiveness of large scale national programs for the 
prevention of mother to child transmission (PMTCT) of human immune virus (HIV) in 
sub-Saharan Africa remains limited. 
Primary objective 
The primary objective will be to measure the effectiveness of program for the PMTCT of 
HIV in 3 sub-districts in the Free State province by measuring HIV-free survival in 
children under the age of 2 years, using data collected as part of a larger three country 
study from October 2008 till May 2009. 
Methods 
This study will be a secondary analysis of data collected from a cross sectional 
community household survey, using multistage cluster sampling. The catchment area 
for each of the facilities where infants were delivered was mapped and divided into 
clusters. A sample of clusters was selected and within each cluster, a random sample of 
households was visited. If there was a child born in the previous 2 years in the 
household, the mother-child pair was eligible for the study. Logistic regression will be 
used to determine risk factors associated with HIV transmission and survival. 
Ethics 




HIV/AIDS remains a major public health issue with 1.6 million people having died of 
AIDS-related illnesses worldwide in 2012 alone (1). The majority of all infections (69%) 
were in sub-Saharan Africa (2). In South Africa 200,000 deaths in 2013 were due to 
HIV/AIDS and 6,300,000 people were living with HIV and the majority of infections were 
among women (3).  
HIV can be transmitted from an HIV-infected woman to her child and this is called 
mother to child transmission (MTCT) during pregnancy, labour and delivery and 
breastfeeding. MTCT of HIV is also known as vertical transmission. The overall HIV 
prevalence among women attending antenatal health care centres was 29.5% (95% CI: 
28.8 to 30.2%) in 2012. Mother to child transmission of HIV is more likely in women, 
from poorer backgrounds, with less education, who did not receive any form of PMTCT, 
who did not exclusively breast feed or exclusively provide replacement feeding and who 
were unemployed. Studies show that interventions where the mother received HAART 
and where the child received ARV prophylaxis have the greatest impact on HIV 
transmission and HIV-free survival (4-7). 
HIV transmission from mother to child is also more likely to occur in younger women. 
This could be due to the fact that younger women were infected with HIV more recently 
and therefore had higher HIV viral loads (8-11). Socio-economic status is associated 
with vertical transmission, but this maybe because it is associated with unemployment, 
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a lower level of education or a combination of variables that impact on socio-economic 
status.   
Prior to the advent of the HIV epidemic, many studies showed that children who were 
exclusively breast fed for the first six months of life were more likely to survive than 
children who received replacement feeding or mixed feeding. They were less likely to 
have diarrhoea, lower respiratory infections and otitis media. Initially children of HIV-
infected mothers were advised to receive replacement feeding, as HIV transmission 
was more likely to occur through breast feeding.  Recent studies show that mothers who 
are receiving HAART are unlikely to transmit HIV through breast feeding and thus 
exclusive breast feeding is promoted in resource-limited settings, because of the risk of 
co-morbidities in children who are not breast fed.  
Rapid implementation of PMTCT interventions in many countries, including South 
Africa, has led to a substantial reduction in the number of children infected perinatally. 
The reduction in infant mortality as a result of HIV is a result of effective HIV programs 
and increased survival of infected mothers (12). The dramatic decline in perinatal HIV 
infection has been most prominent in the resource rich countries such as the United 
States of America (13). In the first national survey of the PMTCT program in South 
Africa in 2010, the overall transmission rate from mother to child was 3.5% and  in 2014 
the rate was 2.7% (14).  
PMTCT effectiveness 
Assessment of the effectiveness of PMTCT programs encompasses the evaluation of 
the long-term aggregate effect of programs over a period of time, such as a change in 
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incidence of HIV and AIDS-related morbidity and mortality. “Effectiveness is described 
as the prophylactic benefit of a PMTCT intervention when implemented in everyday 
practice” (15). It is the function of how much the antiretroviral therapy reduces the risk of 
MTCT or efficacy and the proportion of the intended population at risk that accesses 
and uses the intervention correctly or coverage. The most common measurement of 
PMTCT effectiveness is the evaluation of coverage only.  
PMTCT services in Free State Province 
Free State is one of the provinces with the highest burden of HIV in South Africa. In 
2012 Free State had the third highest prevalence of HIV at 32.0% (95%CI 29.8 to 
34.3%) among women attending antenatal services in the public sector followed by 
KwaZulu-Natal and Mpumalanga (16). In 2001 eighteen sites were set up by the 
national HIV/AIDS Directorate as pilot PMTCT programs and lessons learned from 
these pilot sites were then transferred to a wider program. Free State was one of the 
first provinces that implemented PMTCT pilot studies. The PMTCT program was 
expanded in 2003 to all antenatal clinics and professional nurses were trained on 
PMTCT control, lay councillors were trained to provide HIV counselling and testing 
(HCT) and district officers provided additional support (17). In 2005 HCT was integrated 
with PMTCT services (17, 18).  In 2007 the PMTCT program was evaluated in three 
sub-districts in the Free State as part of a wider study of PMTCT in four African 
countries.
Despite the presence of data showing the efficacy of a wide range of programs to 
prevent MTCT under ideal conditions in trials, there is a lack of understanding of the 
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health systems or operational requirements required for programs to be effective. 
Measuring HIV transmission rates is not sufficient as children born to HIV infected 
mothers but who do not become infected are at higher risk of morbidity and mortality 
compared to those that are not infected. Currently, there is no consensus gold standard 
to adequately measure population effectiveness of PMTCT programs and it is difficult to 
monitor the implementation of coordinated programs, where resources are constrained 
(19). In addition, there is a lack of complete and accurate routine information making it 
difficult to accurately measure effectiveness of programs (20, 21).  
Problem statement 
Although there have been significant advances in the implementation of PMTCT 
interventions particularly in sub-Saharan Africa, there were 390 000 new paediatric HIV 
infections in 2010 and over 90% occurred in sub-Saharan Africa (22). A developed, 
well-functioning and widely accessible health care system is a requirement for an 
effective PMTCT program. This is not the case in many resource limited settings as 
there are challenges including a lack of trained health care providers, poor client 
adherence, stock outs and a poor state of the physical infrastructure of the health care 
system (23). 
Different approaches of measuring the effectiveness of PMTCT programs 
Several techniques have been used to monitor the effectiveness of PMTC programs 
(15).This includes the use of mathematical modelling however accurate and reliable 
data is required for this purpose. A number of study designs have been used to monitor 




In this study HIV-free survival will be used to measure PMTCT effectiveness. It is an 
ideal measure particularly in resource poor settings like the Free State, because it not 
only measures the direct benefits of the program such as prevention of infections and 
deaths but it also integrates the benefits in children who are exposed but do not become 
infected with HIV. HIV-free survival measures both the quality of antenatal and obstetric 
care as well as post-natal care and evaluates PMTCT effectiveness at the population 
level rather than at the facility level only, as is usually the case in most studies.  
Study rationale 
 
Several studies have been conducted in lower and middle income countries to measure 
the effectiveness of PMTCT programs using different methodological approaches and 
outcomes. Most PMTCT studies have been limited to evaluating the effectiveness of 
interventions in preventing in utero and intrapartum transmission of HIV.  These studies 
have provided little information on the long term effects of different feeding practices 
and ART prophylaxis provided to the mother and new-born, on the transmission of HIV 
and or child survival.  
The outcome HIV-free survival is a better measure as it incorporates the effects in 
exposed children who do not become infected as well as factors associated with 
survival. Population-based studies such as household surveys have the added benefit of 
including women who may not have attended antenatal services or who did not deliver 
in a health care facility.  
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Objective 
1. The primary objective will be to evaluate the effectiveness of the PMTCT
program by comparing HIV-free survival in children less than two years of age,
who have been exposed to HIV, with survival in unexposed children in Free State
province. Factors associated with survival will also be determined.
. 
2. The secondary objective of the study will be to determine risk factors that are
associated with HIV transmission among children exposed to HIV, taking into
account the PMTCT exposure status of the mother.
Methodology 
Study design  
This study will be a secondary analysis of data from the PEARL study that was a multi-
country evaluation of the PMTCT program in communities in Cameroon, Côte d’Ivoire, 
South Africa, and Zambia between 2008 and 2009. This was a cross sectional 
community survey. 
Study population 
The study population was all women who had given birth to a child in the previous two 
years in the catchment area of maternity facilities in three randomly selected sub- 
districts in the Free Sate. Mothers were interviewed and socio-demographic information 




Study sampling was part of the original study. Multistage cluster sampling was 
employed. The catchment area for the maternity services in the three randomly selected 
areas, were mapped. The area was divided into clusters based on the census sub-
areas and 30 out of 210 clusters were randomly selected. A random starting point was 
selected in each cluster. Systematic sampling was used and sampling was continued 
until the required number of households, with children born 2 years prior to the study 
were identified, and mothers consented to be included in the study. 
Information about the survey was disseminated throughout the community by means of 
door to door sensitization, announcement of survey information, broadcasting on radio, 
involvement of local and familiar leaders that were known around the community, 
printed material to promote participation, questionnaire uptake and collection of blood 
specimens in the community 
Mothers (who may be dead or alive) in the household were included in the study if they 
had given birth to a child.  In cases where no one was home to participate in the 
interview, two additional attempts were made to identify an eligible mother in the 
household. The study was conducted between November 2007 and April 2008. 
Sample Size 
We hypothesize that survival will be lower in children born to HIV infected mothers. The 
required sample size was thus calculated by assuming 70% of children born to HIV-
infected mothers would survive, whereas 90% of children born to uninfected mothers 
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would survive. As we wanted 80% power to detect this 20% difference with α=.05, we 
required a sample of 246 mother-infant pairs.  
Data collection 
Trained field workers interviewed mothers and collected the data under the supervision 
of trained supervisors and study coordinators. Field workers were women from the 
same communities where the study was being conducted. Interviewers were trained on 
the importance of ensuring privacy and confidentiality at all times. All identifiers were 
removed from the interview schedules once the interview was completed. The 
questionnaires were checked manually for errors during the fieldwork by supervisors 
and co-ordinators.  Data was double captured by trained personnel.  
Study questionnaire 
The study questionnaire was based on several District Health Survey questionnaires 
used in different countries.  Socio-demographic and socio-economic variables were 
collected at each household. These included type of water supply, level of education, 
and antenatal and delivery care received, with a special focus on PMTCT service 
utilization. The child questionnaire included the type of delivery, the medications given 
to the mother around birth and the weight of the infant at birth. 
Table 1 shows variables that will be used to determine risk factors associated with HIV-
free survival. These factors include demographic information including age, level of 
education, employment and education status of the mother. The variable received 
PMTCT was categorized into those who received any form of PMTCT and those who 
received no PMTCT. The study collected data on socio-demographics as well as socio-
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economic status and data on water supply and electricity to assess general living 
conditions and the state of the environment. 
Table .1. Variables that may be associated with HIV-free survival. 
Variable Type 
Outcome (HIV status outcome of child) Categorical-Binary 
Negative 0 
Positive 1 
Sex of child Categorical-Binary 
Female 1 
Male 0 






Education level Categorical-ordinal 




Employment status Categorical-Binary 
Yes 1 
No 0 
Feeding status Categorical 
Exclusive breastfeeding 0 
Replacement feeding 1 
Mixed feeding 2 
Mother received PMTCT prophylaxis Categorical-Binary 
Mother received any form of PMTCT 
prophylaxis 1 
Mother received no PMTCT prophylaxis 0 
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Specimen collection and testing 
All mothers with children born in the two years prior to the study, were asked to provide 
blood for HIV testing. Blood was obtained from children either by means of a heel-prick 
or finger-prick in order to obtain a dried blood spot. All blood tests were conducted 
anonymously in a laboratory after the field workers had left the household. Children of 
infected mothers were tested for HIV infection using HIV DNA PCR.  Mothers were 
tested with rapid HIV antibody tests. The specimen collection was done only once 
written consent was obtained. All participants were advised to attend their local health 
clinic for individual HIV counselling and testing.  
Reliability and Validity 
The questionnaire was pretested before the study was commenced in order to identify 
the validity of the tool. A pilot study was conducted to determine the feasibility and 
acceptability of the study. A percentage of households were revisited to determine the 
reliability of data. 
Data management and analysis plan 
Data from the PEARL study will be obtained and captured using Microsoft Excel and the 
analysis will be performed on Stata 11 (StataCorp. 2012. Stata Statistical Software: 
Release 11. College Station, TX: StataCorp LP.).  Descriptive and analytical statistics 
will be performed in order to understand the data using frequency tables, box and 
whisker plots and histograms. Furthermore, logistic regression analysis will be 
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performed to determine which of the risk factors are associated with HIV transmission 
and HIV-free survival. 
Ethics 
All data provided for this secondary analysis was anonymised before the initial four 
country analysis was conducted. There is no link to the name or address of participants.  
The protocol for this secondary analysis will be submitted to the Human Research 
Ethics committee of the University of Cape Town. The study will adhere to the principles 
as declared in the Helsinki Declaration of 2008 and the South African Medical Research 
Council guidelines on Ethics for Medical Research. There are no risks to participants as 
the data has already been collected. Potential benefits of the study include improved 
knowledge and understanding of the methodology to measure effectiveness of PMTCT 
programs over time. This will primarily benefit the health care system and the 
community of Free State province. 
Dissemination of findings 
The finding will be disseminated to stakeholders in the form of a report coupled with a 
brief presentation. The findings of the study will be disseminated to the broader 
scientific community by publishing the findings in a peer-reviewed journal.
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 Epidemiology of HIV/AIDS 
 
HIV continues to be a major public health issue. By 2012,  36 million people had died as 
a result of HIV/AIDS and 1.6 million people died of AIDS related illnesses worldwide in 
2012 alone (1).  About 17.7 million women worldwide were living with HIV in 2012, and 
the prevalence of HIV among women between 30 to 34  years of age was the highest  
at 42.8 % in 2012 in South Africa alone (2). The majority of all infections (69%) are in 
sub-Saharan Africa (1). In addition, 9.7 million HIV-positive people were receiving ART 
in low and middle income countries in 2012. The Millennium Development Goal (MDG)  
number 6 calls for  “prevention of infection among young people including information, 
HIV testing and condom provision, the prevention (eradication) of mother to child 
transmission, and improving treatment and care of children and young people infected 
with HIV”. Hence the government  attempted to meet the NSP’s targets and reduce the 
MTCT rate of HIV to less than 5% by 2011 to meet the 4th and 6th Millennium 
Development Goals (MDGs) that were aimed at reducing by two thirds the under-five 









HIV/AIDS IN sub–Saharan Africa 
 
Sub-Saharan Africa is the epicenter of the HIV pandemic with an estimated 25 million 
people living with HIV in this region.  Furthermore, 2.9 million children younger than 15 
years of age in sub-Saharan Africa are living with HIV and an estimated 190 000 deaths 
occurred in children in 2012 (3). There has been an increase in the prevalence of 
persons infected with HIV as the number of people receiving antiretroviral treatment has 
increased dramatically. A recent study in KwaZulu-Natal reported an increase in HIV 
prevalence among people aged between 15-49 years of age after scale-up of 
antiretroviral treatment in rural KwaZulu-Natal where the percentage of HIV infected 
people on ARVs increased from 0% in 2004 to 31% in 2011 and the prevalence of HIV 
increased from 21 to 29% (4). This increase in prevalence is a result of decreased 
mortality from AIDS as HIV positive people live longer. Approximately 49% of people 
living with HIV and in need of ART in the region were receiving therapy by the end of 
2010 and 2 million people worldwide were newly enrolled on antiretroviral treatment in 
2013 which was the largest ever annual increase (5). Three countries in sub-Saharan 
Africa with epidemics that are generalized, Botswana, Namibia and Rwanda have 
attained universal access to ART. In Swaziland and Zambia coverage is estimated to be 
70% and 79% respectively (1). However the progress with coverage has been variable 
across sub-Saharan Africa.  
In South Africa it is estimated that 6,300,000 people were living with HIV and 200,000 
deaths occurred in 2013 (4). The highest prevalence being 19.1% amongst adults aged 
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between 15 to 49 years (4). In women older than 15 years of age 3,500,000 were living 
with HIV and there were 360,000 children less than 14 years of age living with HIV (4). 
A diagnosis of HIV infection is confirmed by blood tests which detect the presence HIV 
antibodies. Currently, there is no cure for HIV infection however it can be controlled 
through the effective use of antiretroviral therapy (ART). 
Mother to child transmission of HIV (vertical transmission) 
HIV can be transmitted from an HIV-infected woman to her child and this is called 
mother to child transmission of HIV (MTCT). It may occur during the course of the 
pregnancy, labour, delivery or during breastfeeding.  In 2012 it was estimated that 1000 
children were newly infected with HIV each day and the majority of these new infections 
were among children in sub-Saharan Africa (3). The coverage of prevention of mother 
to child transmission (PMTCT) services has substantially increased recently and fewer 
infants are acquiring HIV.  In 2012 410 000 children aged between 0 to 14 years were 
living with HIV in South Africa. It is estimated that there had been a 49% decrease in the 
prevalence of HIV from 2002 to 2012 due to the introduction of PMTCT programs (6). 
The scaling up of antiretroviral programs had resulted in a 20% reduction in child 
mortality over the same period (7). 
Several factors increase the risk of transmission of HIV from mother to child. HIV 
transmission from mother to child is high during delivery as the infant is exposed to 
blood and other fluids including amniotic fluid as they are passing through the birth 
canal, especially for those women who are not receiving any form of intervention. For 
HIV positive women who are not on treatment, there is 25% chance of passing the virus 
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to their child during pregnancy, labour, delivery and the risk of transmission is increased 
during breastfeeding by an additional 12% (8, 9). Feeding practice is one of the major 
factors that have been extensively investigated regarding transmission of HIV. Prior to 
the advent of the HIV epidemic, many studies showed that children who have been 
exclusive breast fed for the first six months of life were more likely to survive than 
children who received replacement feeding or mixed feeding. They were less likely to 
have diarrhoea, lower respiratory infections and otitis media. Initially children of HIV-
infected mothers were advised to receive replacement feeding, as HIV transmission 
was more likely to occur through breast feeding.  Recent studies show where mothers 
receive HAART and or infants receive ART prophylaxis, HIV transmission through 
breast feeding is unlikely and thus exclusive breast feeding is promoted in resource-
limited settings, because of the risk of co-morbidities in children who are not breast fed. 
Even where mothers are not able to access HAART or ART prophylaxis for infants, the 
risk of death in in infants on replacement feeding exceeds the risk of MTCT through 
breastfeeding during the first 4 months of life, under conditions of poverty and poor 
hygiene and therefore exclusive breastfeeding is promoted.  (10).  
A cohort study was conducted in 2001 in Durban, South Africa including 551 pregnant 
women that were HIV positive who either exclusively breastfeed or formula feed. Those 
that were breastfeeding were encouraged to breastfeed for 3 to 6 months.  The study 
found that infants who were exclusively breastfed for  3 months were less likely to 
acquire HIV in a period of 6 months compared to those who were never breastfed, the 
risk being 0.194 (95% CI 0.136-0.260) and 0.194 (95% CI 0.125-0.27) respectively (11). 
The effect of breastfeeding is more pronounced when the mother and infant are taking 
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ARVs during the period of breastfeeding (12-14). ARVs prevent replication of HIV and 
reduce the viral load in breastmilk (13). Re-infection with HIV during pregnancy is an 
important risk factor for transmission of HIV in utero, intrapartum and postpartum via 
breast milk. Risk doubles when compared with women with established infection 
because of high viral load associated with new infection (15, 16). 
Socio economic status is associated with HIV status in women. Factors that affect 
socio-economic status include the “total measure of person’s work experience and of 
individual’s or family’s economic and social positon in relation to others, based on 
income, education, and occupation” (17). A cross-sectional study in Kenya looking at 
the association between demographic, social, biological and behavioural variables and 
HIV serostatus found that wealth was positively associated with positive HIV serostatus. 
Women with primary education were more likely to be HIV infected than those with no 
education (OR=1.9) (18). Another study found unemployment was associated with 
delayed access to treatment for HIV (OR=1.41, 95% CI 1.14 to 1.74). Post-secondary 
education was associated with a reduced risk of becoming infected with HIV (HR=0.80, 
95% CI: 0.71 to 0.91) (19). These finding were consistent with other studies (20, 21), 
but inconsistent with others (22, 23). Other studies show that the maternal age is 
associated with HIV.  Children born to mothers aged between 15 to 24 years were more 
likely to be infected than children born to women of 35 to 39 years of age (24). Birth 
weight is also an important factor when investigating mortality due to HIV, low birth 
weight infants in particular have been reported to have a much higher risk of mortality 
and morbidity in infancy and early childhood (25, 26) 
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PMTCT interventions may reduce the rate of transmission to less than 1% (12, 14, 27). 
However, coverage is suboptimal as some pregnant HIV-infected women fail to access 
PMTCT services (28, 29). In 2012 the HIV prevalence among women attending 
antenatal services in the public sector in South Africa was 29.5% (95% CI: 28.8 - 
30.2%). It has stabilized over the past 5 years. In 2011 vertical transmission of HIV was 
reported to be 2.7% (30). Despite the widespread implementation of PMTCT services in 
South Africa challenges still remain. 
Exposure to HIV in utero, during delivery and through breast feeding has a substantial 
impact on morbidity and mortality, particularly in the first year of life. HIV-infected 
children demonstrate delays in development, deficits in functional health, increased 
opportunistic infections and highlight the need for increased uptake of early infant 
diagnosis and provision of ART for all infected infants (31-34). A cohort study in Malawi 
reported that HIV-infected children had significantly poorer health outcomes than HIV-
unexposed children and HIV-exposed but uninfected children at 20 months. These 
included hospital admissions, delayed development, undernutrition and restriction in 
function (35). A meta-analysis in sub-Saharan Africa reported a cumulative mortality 
rate of 174/1000 live births among HIV-exposed children at 24 months (36). This further 
highlights the need for effective PMTCT programs to reduce child morbidity and 
mortality. The PMTCT Plus initiative where pregnant women are initiated on ART for life 
not only addresses vertical transmission of HIV but also impacts on the health and 




Review of evidence from PMTCT studies of ARV Prophylaxis 
 
The earliest study of the efficacy of ARV prophylaxis to prevent MTCT was conducted in 
the United States of America (US). It was a randomized double blind controlled trial to 
determine the efficacy and safety of Zidovudine (ZDV) given during pregnancy and 
labour to the mother and to the infant for six weeks postpartum. HIV-positive women 
were randomly assigned to either short course Zidovudine (SC_ZDV) administered to 
mothers from 14 weeks of pregnancy and during delivery and for 6 weeks postnatal or 
placebo.  The study showed a 66% reduction in the risk of transmission (37).The rate of 
transmission of HIV from mother to child was 22.6% in the placebo arm while it was 
7.6% among those that were in the SC-ZDV arm. This trial was followed by various 
RCTs in Africa and Thailand.  
The HIVNET012 trial conducted in Uganda provided nevirapine to mothers during 
labour and to infants within 72 hours of birth in the treatment arm and Zidovudine was 
given to mothers during labour and for 7 days thereafter to infants in the control arm in a 
breastfeeding population (37). Findings revealed a transmission rate of 11.8% in the 
treatment arm and 20.0% in the control arm at 6 to 8 weeks. This reduction was 
sustained at 18 months, with a rate of 15.7% and 25.8% in the treatment and control 
arms respectively (37). However, the biggest challenge was to rapidly translate study 
findings into policies to reach millions of HIV infected pregnant women in developing 
countries.  The policy was difficult to implement in many African countries because of 
weak health care systems. 
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Strategies to prevent transmission of HIV 
In developed countries with strong health systems the risk of vertical transmission of 
HIV has been reduced to less than 1%. A good PMTCT service requires a well-
functioning health system (38). In order to decrease vertical transmission, antenatal 
care should include HIV counselling and testing and the receipt of prophylaxis for the 
HIV infected mother and infant. This requires well-functioning obstetric care antenatally 
and intrapartum and child health services postnatally. The minimum antiretroviral 
prophylactic regimen recommended in resource poor settings is single-dose nevirapine 
in labour because of its low cost, easy administration, rapid absorption and relatively 
long half-life.  Best practice includes the provision of Highly Active Antiretroviral 
Treatment (HAART), delivery through elective caesarian section and appropriate 
feeding practices including either exclusive breast feeding if a mother has been on 
ARVS for 3 to 6 months and has an undetectable viral load or replacement feeding (39, 
40). Replacement feeding is often not acceptable, feasible, safe or sustainable in 
resource limited settings (41, 42), and hence exclusive breastfeeding with antiretrovirals 
provided to the mother, is recommended (43, 44). In addition, with improved access to 
antiretrovirals (ARVs) more pregnant women are on ARVs before becoming pregnant. 
Current WHO guidelines recommend HAART for all HIV-positive pregnant women 
regardless of their CD4 count and they are encouraged to remain on treatment until 
they complete breastfeeding. A fixed-dose combination of three antiretrovirals is 
recommended to reduce the pill burden.  
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Challenges faced by PMTCT Programs in Sub-Saharan Africa 
 
Antiretroviral programs encounter many challenges in sub-Saharan Africa(45). These 
challenges include the lack of trained personnel to initiate antiretroviral therapy and 
poorly developed drug procurement and distribution services. Health care workers 
require training on treatment, monitoring of adherence and counselling of HIV infected 
pregnant women. Viral load monitoring to effectively monitor the response to 
antiretroviral therapy is expensive and requires sophisticated technology that is not 
always available. These challenges are more complex in resource poor settings such as 
in South Africa (45-48). 
PMTCT in South Africa 
 
PMTCT rollout in South Africa 
 
The first PMTCT program in South Africa was initiated by the Provincial Government of 
the Western Cape (PGWC) in Khayelitsha in 1999 despite being opposed from the 
National Ministry of Health at the time. The program included voluntary counselling and 
testing (VCT) and this was provided at one midwife obstetric unit (MOU) and AZT was 
dispensed by midwives from 36 weeks gestation and during labour. This was a pilot 
study that was later expanded to another MOU. However, there were no HIV services 
available for the mothers post delivery. Due to political resistance there was a delay in 
the implementation of PMTCT services elsewhere despite studies showing the 
effectiveness of PMTCT interventions. In 2002 the Western Cape launched the first 
province-wide PMTCT program despite resistance from the National Ministry of Health. 
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In 2003 pilot PMTCT programs were introduced in the rest of South Africa. Single-dose 
nevirapine (SD NVP) was offered to the mother in labour and to the infant within 72 
hours of delivery. This intervention was coupled with modified obstetric practices, 
counselling on infant feeding options and free replacement feeding to HIV-positive 
mothers in order to avoid transmission through breastfeeding (49). Following the pilot 
programs, the South African government implemented the first nation-wide PMTCT 
program in 2004. In 2008 the national guidelines for pregnant women were amended by 
introducing dual therapy. Pregnant women received AZT from 28 weeks of pregnancy 
and Sd-NVP was provided during labour and to their infants with AZT. In addition 
provided-initiated counselling replaced voluntary counselling and testing. 
The guidelines were further modified in 2010 to include routine HIV testing and 
counselling for all pregnant women. In addition women with a CD4+ T-cell count less 
than 350 cells/mm3 were placed on HAART. In 2011 exclusive breastfeeding was 
recommended for all mothers and replacement feeding was reserved for medical 
conditions. In 2013, the guidelines were modified further to prioritise the initiation of 
HAART for women with severe HIV disease (WHO staging of either 3 or 4) regardless 
of their CD4 cell count. Currently HAART is recommended for all HIV-infected pregnant 
women with the use of a fixed dose combination of three ARV’s to promote adherence.  
PMTCT services in Free-State 
 
In 2012 Free State had the third highest prevalence of HIV at 32.0% (95%CI 29.8 to 
34.3%) among women attending ANC services in the public sector followed by 
KwaZulu-Natal and Mpumalanga (50). The first PMTCT pilot sites were initiated in 2001 
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in the Free State in 2 resource-limited sites in Frankfort and Virginia. Initially there was 
low rate of acceptance of HIV testing. In 2002 the sites ran out of rapid kits for testing 
for HIV for three months and during this period, specimens had to be sent to a central 
laboratory and hence there were missed opportunities for initiation of therapy as some 
of those women who tested failed to return to collect their results. The sites also ran out 
of nevirapine (51, 52). The Free State was the province with the highest rate of breast 
feeding in South Africa and 64% of mothers breastfed (51). In 2003 the PMTCT 
program was expanded to all antenatal services. Professional nurses were trained on 
the PMTCT protocol, operational plans were developed and implemented and 
replacement feeding was provided for those who chose that option. Lay counsellors 
were trained to provide HCT. In 2007 the PMTCT program was evaluated in three sub-
districts in the Free State as part of a wider study of PMTCT in four African countries. 
Despite the presence of data showing the efficacy of a wide range of programs to 
prevent MTCT under ideal conditions in trials, there is a lack of understanding of the 
health systems or operational requirements that are required for programs to be 
effective. Currently, there is no consensus gold standard to adequately measure 
population effectiveness of PMTCT programs and it is difficult  to monitor the 
implementation of coordinated programs where resources are constrained (53). In 
addition, there is a lack of complete and accurate routine information making it difficult 
to accurately measure effectiveness of programs (54, 55). Studies are therefore 
required to evaluate and monitor effectiveness of PMTCT program and compare 
progress across programs.  
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Review of PMTCT effectiveness 
 
Effectiveness is described as the prophylactic benefit in terms of intended and desired 
outcomes of a PMTCT intervention when applied in everyday practice (56). 
Effectiveness is a product of efficacy and coverage. If coverage is optimal, effectiveness 
should match the efficacy observed during clinical trials for the population in which the 
efficacy trial was conducted (56). Effectiveness is a function both of how much the 
prescribed therapy reduces the risk of mother to child transmission (MTCT) or efficacy 
and the proportion of the intended population at risk that accesses and uses the 
intervention correctly or coverage. Testing for HIV in antenatal clinics is the entry point 
into the PMTCT program and high coverage at every step helps reduce opportunities 
that may be missed to prevent MTCT and improve effectiveness. A study showed that 
coverage of HIV testing and receipt of results by mothers was 98.8% at antenatal 
services but there was a steady decline in coverage thereafter, but only 78.3% of those 
mothers that were HIV positive got a CD4 count, of whom 91.8% received appropriate 
ARV prophylaxis according to the protocol (57). 
Several studies have been conducted to determine the efficacy of various ARV 
regimens administered during the intrauterine, intrapartum and postnatal period to 
reduce transmission of HIV from mother to child. When measuring effectiveness the 
numerator represents the number of people who are eligible for treatment who receive 
it, while the denominator represents the population at risk. Coverage is explained as the 
product of a pathway called the PMTCT cascade which consists of events that must 
occur in order for the prophylaxis to be administered (58, 59).  The PMTCT cascade is 
built from indicators that are routinely collected by facilities that provide PMTCT. Figure 
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1. below details the steps of the cascade beginning with the woman agreeing to HIV
testing, accepting the positive result, agreeing to be part of the program, accessing 
ART, adhering to the regimen, adhering to the infant regimen and HIV testing for the 
infant at 6 weeks and later if required.  Each step of the cascade is critical in ensuring 
the success of the program as attrition at each point will have an impact overall. A study 
assessing the acceptability and effectiveness of a PMTCT program in Côte d'Ivoire and 
Burkina Faso showed that after testing positive for HIV, women refused short course 
ZDV during pregnancy and the overall coverage was low (58). Further studies in Cote 
d’lvoire, Burkina Faso and Kenya showed that 60% of HIV-infected women refused the 
antiretroviral prophylaxis offered (58, 60). Reasons for rejecting prophylaxis included 
lack of education, not fully understanding the purpose of prophylaxis, denial and fear of 
stigma from members of the community (61) 
Attend institutional 
antenatal care 
Accept HIV test 
Obtain HIV test results 
Agree to ARV prophylaxis 
Adhere to ARV prophylaxis 
Adhere to infant ARV doses 
Be offered HIV test 
HIV-infected women only 
All women presenting for 
delivery 
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Figure 1. PMTCT cascade for coverage. Source (56) 
Ways to evaluate PMTCT programs 
PMTCT services are located in antenatal and maternity clinics and data are easily 
accessible for linking mother-infant pairs through medical records and data from the 
PMTCT cascade. It is also easy to acquire specimens, for example from cord blood 
after mothers have delivered. Data is collected at one point in time or retrospectively 
using facility-based studies (56, 62). Facility-based studies are convenient because 
sampling units can be easily obtained (62). These include facility based cross-sectional 
studies used to estimate program effectiveness that are simpler and less expensive 
than prospective designs as data are collected at one point in time or retrospectively. 
Measuring PMTCT effectiveness has been conducted through population-based 
surveys that gather cross-sectional or retrospective data. All households where a child 
(dead or alive) was born in the previous two years are identified and the HIV status of 
women who have delivered a child in the previous year and the HIV status of exposed 
children can be determined (54, 59, 63, 64). These studies are useful in describing the 
burden of disease and provide population based outcomes since the entire population is 
included in the study (56). 
A cross sectional study was conducted in Khayelitsha in 2005 to measure PMTCT 
effectiveness. It used facility based approach to identifying infants born to HIV-infected 
mothers who accessed PMTCT. The study selected 535 mother-infant pairs from 
antenatal PMTCT registers and they were able to identify 71% of these mother-infant 
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pairs around six weeks of age. At that time mothers were given Zidovudine (AZT) from 
34 weeks gestation and during labour, while those who received less than 2 weeks of 
AZT were also given single dose NVP in labour. The rate of transmission was 8.8% 
(95% confidence interval 6.2–10.9%). A limitation was that it could not be ascertained 
whether those that were untraced had died from HIV (62). The disadvantage of facility-
based information is that it is limited to pregnant women who attend antenatal and 
delivery services, and there is no information on women who do not attend. Hence 
facility-based data may be biased towards better outcomes as women have attended 
services. Use of retrospective data in survey studies may detect trends over time. If the 
program has been running for a number of years, the survey can be used to compare 
outcomes that are stratified by the age of children and can provide cohort data that can 
evaluate the PMTCT program. A potential disadvantage of this survey approach is recall 
bias as it relies heavily on patient recall for information on PMTCT. 
In 2005 the performance of South Africa’s national pilot PMTCT program was reported 
using routine PMTCT program data collected from the 10 pilot sites from January to 
December of 2002. The study identified health system constraints to program 
effectiveness and optimal coverage. It showed that acceptance of HIV testing was poor, 
delivery of nevirapine to mothers was low and that it was difficult to track mothers 
postnatally to test infants at 12 months. Infant feeding practices suggested that there 
was inadequate counselling on the possible negative effects of replacement feeding 
(54). The study led to the review of feeding practices and recommendations on the 
importance of exclusive breast feeding. 
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The first major national evaluation to determine effectiveness of the PMTCT program 
was conducted in 2010. The study was a cross-sectional facility-based study which 
looked at MTCT rates 6 weeks postpartum at immunization sites in all 9 provinces. The 
study included 10 178 HIV exposed infants and the transmission was 3.5% (95 % CI 2.9 
to 4.1). The uptake of services for PMTCT was high with 98% of women getting tested 
and 91.7% of those who were found to be positive received ARV prophylaxis. However 
only 35% of mothers indicated that they would take their infants for early infant 
diagnosis, indicating that opportunities to identify and care for HIV infected infants early 
would be missed (65). In 2011 a second facility based survey of PMTCT effectiveness 
was conducted. It was the first national evaluation of WHO Option A that included a 
change to exclusive breastfeeding in women who were taking ARVs. The study 
measured transmission rates in infants around 6 weeks of age attending immunization 
services. The survey found that vertical HIV transmission had decreased from 3.5% in 
2010 to 2.7% (95% CI 2.1 to 3.2%) in 2011. In addition, the quality of counselling on 
infant feeding had improved and women were more likely to exclusively breast feed 
(66).  Another study indicated that despite the fact that 95% of infants identified as 
exposed to HIV at antenatal clinics were tested for HIV,  exposed infants  of mothers 
who did not attend antenatal care and those who do not access HIV testing during 
antenatal and intrapartum care would be missed (67). A recent study using HIV PCR 
test data from 2003 to 2012 from the laboratory information system demonstrated that 
there had been rapid scale-up over the first decade of the PMTCT program, with 73% of 
the estimated 270 000 HIV-exposed infants having an early PCR test and that early 
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transmission had fallen to 2.4% as a result of successful implementation of the PMTCT 
program (68). 
Other facility based studies have used the strategy of linking anonymous cord blood 
specimens to evaluate PMTCT effectiveness. Nevirapine is easily detected in cord 
blood through chromatography as it readily crosses the placenta, gets absorbed and 
has a long half- life. Coverage is determined from the proportion of mother-infant pairs 
of HIV infected women where there is evidence that both the mother and infant received 
antiretrovirals. As specimens are anonymous, consent is not required from women to 
test their cord blood (60, 69). In addition, data from clinical records can be linked to cord 
blood data. In 2008 cord blood from 3034 women was collected at delivery in the 
Western Cape. Of the 3034 specimens, 507 tested HIV positive, and 474 (92.7 %) were 
tested for the presence of ART. Fifty eight percent had evidence that the standard of 
care had been provided and 73% had ingested some form of ART prophylaxis. The cord 
blood surveillance indicated a much lower coverage than that reported in the clinical 
records (70). 
In 2003 a similar study conducted in Zambia measured PMTCT effectiveness using 
cord blood specimens from 10194 women delivering in 10 public facilities. The coverage 
was only 30%. There was evidence of failures at a number of points in the PMTCT 
cascade with 18% of HIV positive mothers not being offered HCT and 27% declining 
testing, while 32% of women who were recorded as having been given nevirapine, there 
was no evidence of nevirapine in the cord blood. It was also found that women who 
refused testing during testing were more likely to be HIV positive. Another study 
evaluated effectiveness using cord blood in 2005 and of the 8787 women enrolled in the 
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study 2257 (26%) were HIV positive according to the cord blood. Of these women 1246 
(55%) had received an antenatal HIV test result and only 1112 (89%) were positive 
according to the clinical records. Only 751 of 1112 (68%) positive women who were 
identified by the PMTCT program had evidence of NVP in the cord blood and only 675 
infants (90%) received NVP before discharge. Adherence to both maternal and infant 
prophylaxis was only 30% (675/2257). The study showed that there were losses at each 
step of the cascade (59).  
In 2004 a clinic based study conducted in KwaZulu-Natal evaluated effectiveness 
through anonymous HIV prevalence screening on dried blood spot (DBS) samples from 
all the infants who attended their 6 week immunization clinics. The study determined 
maternal infection by testing for HIV antibodies and for infection in exposed infants 
through PCR. Of the 931 infants who were exposed to HIV (37.4%; 95% confidence 
interval, 35.4–39.4%), 188 infants were HIV RNA positive, resulting in rate of 
transmission that was 20.2% (95% CI, 17.8–23.1%). The rate of transmission was 
15.0% in mothers who had received single-dose nevirapine. This study was one of the 
first to demonstrate that HIV testing of all infants who attended immunization services at 
6 weeks of age identified infected infants early, maximizing the opportunity for early 
treatment. The study showed that screening for HIV at immunization clinics was 
acceptable, feasible and beneficial (71). 
Measuring effectiveness is also largely dependent on the type of data used for the 
study. Community-based data are more valuable because they provide a more 
representative sample as they include women who do not attend antenatal or delivery 
services. PMTCT effectiveness studies may be included in other population-based 
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studies such as Demographic Health Survey (DHS) studies. Some studies have used 
Demographic Health Surveys (DHS) which are simple and have been conducted in a 
number of countries to collect such population-based information. Programs that rely on 
women who accept testing during voluntary testing to determine HIV prevalence may 
under- or over-estimate the true prevalence (55). 
Other studies have used the prospective follow up study design to measure 
effectiveness of PMTCT programs (60, 69, 72, 73). These studies observe participants 
and measure HIV-free survival and compare HIV transmission rates. Although 
measurement of HIV-free survival through cohort studies of large groups of mother-
infant pairs is an ideal measure for measuring PMTCT effectiveness, the limitations 
include loss to follow up and high costs and hence cohort studies are not practical for 
routine monitoring. Individual behaviour may change when observed (the Hawthorne 
effect) and study findings cannot be generalized or applied to other populations (74). In 
addition, with most cohort studies, the investigators are ethically bound to provide 
standard of care and therefore should ensure that mothers are referred for appropriate 
care and this may affect the outcome (69). 
In Côte d’Ivoire infants were followed for 12 months to evaluate the short term (4 week) 
and longer term (12 months) effectiveness of a two-tiered PMTCT strategy. Women 
meeting the WHO eligibility criteria received HAART and those with less advanced HIV 
disease were given short-course antiretroviral PMTCT prophylaxis. The study 
demonstrated that both short- and long-term PMTCT strategies were safe and effective 
in resource-constrained settings (75). Another study evaluated PMTCT program 
effectiveness in rural Kenya and in Cameroon where infants were followed for 24 
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months (60). In both studies loss to follow up was more than 20% introducing selection 
bias (60, 69).  Another cohort study of antenatal clinic attendees was conducted in rural 
Kenya to determine the effectiveness of short-course ZVD for PMTCT in a 
breastfeeding population between 1996 and 1998. Of the 216 HIV-infected mothers 
followed for 24 months, 51 (23.6%) completed the regimen, 69 (31.9%) only competed 
the prepartum portion, and 96 (44.4%) never completed any portion of the regimen. The 
major reasons for nonadherence were the occurrence of labour earlier than expected 
and delivery at home. At 2 year, 75 of the children exposed to HIV (34.7%) and 33 HIV 
positive mothers (15.3%) had died and almost 30% of HIV exposed infants were lost to 
follow up. The HIV-free survival of children at 24 months of age was associated with 
survival of the mother and pre-partum ZDV compliance (60).  These findings highlight 
the problems associated with the implementation of PMTCT programs in rural areas in 
Africa. There were also socioeconomic and cultural barriers to access to care. A further 
limitation of the study was selection bias as recruitment was voluntary and women with 
a life threatening illness and single women were excluded from the study. Another study 
conducted in Malawi determined the acceptability of voluntary counselling and testing 
for HIV. The study provided information on the prevention of HIV/AIDS, emphasizing 
mother to child transmission, after which mothers had the right to either delay or refuse 
test. The study included 3136 mothers attending antenatal services for the first time, 
and 2996 were counselled prior to testing, 2965 were tested for HIV, all of whom were 
post-test counselled. Thirty one mothers (1%) refused testing and 646 (22%) individuals 
were found to be HIV infected and 238 (45%) of these mothers and 222 (34%) of these 
infants received NVP. The cumulative loss to follow up was 358 (55%) by the 36-week 
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antenatal visit, 440 (68%) by delivery, 450 (70%) by the first postnatal visit and 524 
(81%) by the 6 month postnatal visit. The majority of deliveries (87%) occurred at 
peripheral sites where PMTCT was not readily available (41). 
Other studies of PMTCT effectiveness included observations of consultants and 
interviews with mothers attending clinics. One such study highlighted the need for 
training on counselling particularly regarding optimal infant feeding practices as this 
study showed poor quality of counselling and information provided (76). 
In South Africa the prospective cohort study design was used to measure PMTCT 
effectiveness by following 665 mother/infant pairs where the mother was HIV positive. 
The study was conducted in three sites; Paarl (Western Cape), Rietvlei (Eastern Cape) 
and Umlazi (KwaZulu-Natal) between 2002 and 2004. The women and infants were 
followed for 36 weeks after birth with data collected during home visits until 9 months of 
age. Only 588 pairs (88.4%) were found 3 weeks postpartum. HIV transmission at 3 
weeks of age was 8.6% (95% CI 4.5 to 14.5%) in Paarl, 13.7% (95% CI 8.9 to 19.8%) in 
Rietvlei and 11.9% (95% CI 8.3 to 16.3%) at Umlazi. A high HIV viral load was 
associated with the transmission of HIV or death (hazard ratio 1.54 95% CI, 1.21 to 
1.95). The odds of transmission were 1.5 times higher in participants in the rural site 
compared to those in urban sites after adjusting for potential confounders such as 
socioeconomic status. This study found that PMTCT programs using Sd-NVP 
administered to both mother and child could reduce the early transmission of HIV. The 
study highlighted the need for a well-functioning integrated health system, for optimal 
implementation (72). This study also measured HIV transmission at 36 weeks. The 
cumulative transmission rate at 36 weeks of age was 15.3% in Paarl, 22.4% in Umlazi 
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and 25.6% in Rietvlei. Mortality differed across the 3 sites with Rietvlei showing 
substantially higher mortality. The study identified important predictors of effectiveness 
that needed to be addressed in order to optimize the effectiveness of PMTCT programs. 
These included emphasizing the importance of exclusive breastfeeding and eliminating 
the underlying  and deep seated inequities South Africa health care system (73). 
In 2002 a longitudinal study included 1234 HIV positive women who were given Sd-NVP 
and delivered at Coronation Women and Children’s hospital. HIV transmission was 
8.7% at 6 weeks and 8.9% at 3 months of age indicating the effectiveness of NVP along 
with replacement feeding in reducing the rate of transmission (77). Over 70% infants 
were lost to follow up by 4 months of age and this was the major limitation of this study. 
Other studies have used the retrospective approach. Women attending ANC from 2004 
to 2007 were included and 689 ARV naive women were started on HAART. The mean 
baseline HIV viral load was 101,561 copies/ml. Two percent of women who were 
initiated on stavudine, lamivudine, and nevirapine had an adverse drug reaction, viz. a 
skin rash associated with nevirapine. The CD4 cells/uL count increased by more than 
50 in 80% and viral suppression to less than 1000 copies/ml was achieved in 81% of 
women. The rate of HIV transmission was 5% in the 302 mother-infant pairs who 
completed follow-up for post-natal care. Transmission was 0.3% in the women who 
received more than seven weeks of HAART during pregnancy showing that initiating 





Gap in knowledge 
 
The HIV/AIDS burden globally continues to be a significant public health problem 30 
years into the epidemic. Significant improvements to PMTCT services have been made 
over the years and have shown that vertical transmission can be reduced to less than 
1% in women initiated on HAART. Several techniques have been used to monitor the 
effectiveness of PMTCT programs. Measuring transmission rates alone does not 
provide information on exposed children who do not become infected. It is therefore 
imperative to conduct studies that identify factors associated with HIV-free survival and 
transmission of HIV.  These findings may be used to inform policy and improve the 
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Background: Prevalence of HIV in pregnant women is 30% in the Free State province 
in South Africa and PMTCT services are widely available. The aim was to determine 
effectiveness of PMTCT program by measuring HIV transmission and HIV-free survival 
in children less than two years of age. 
Methods: This was a secondary analysis of data collected from a cross sectional 
community household survey, using multistage cluster sampling. Women who had given 
birth two years prior to the study in the catchment area of three sub-districts that were 
randomly selected in Free State were included. Field workers interviewed mothers, 
identified children who had died. Logistic regression was used to determine risk factors. 
Results: HIV exposure and outcome status was known for 874 (75.50%) of 1158 
children under 2 years of age identified. Ninety seven children (11.10%) were exposed 
to HIV. One exposed (1.03%) and HIV positive child died from an HIV related illness 
while another exposed but uninfected child (1.03%) died from other causes. Thirty 
unexposed children died (3.86%). There was 72% reduction in survival in children who 
were hospitalised at least once since birth while those who breastfed at the time of 
interview were 5.08 times more likely to survive (p<0.001). Being hospitalized at least 
once since birth (p<0.001) was associated with transmission in the adjusted analysis. 
Conclusion: Breast feeding and being admitted to hospital at least once since birth 
were significantly associated with survival and further research is recommended on the 
impact of these factors on transmission and survival. 
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Key words:Free State, South Africa, PMTCT, transmission, survival, multivariate 
analysis 
Abbreviations:  
HIV: Human immunodeficiency virus 
AIDS: acquired immune deficiency syndrome 







The burden of HIV/AIDS continues to be a significant public health problem globally 30 
years into the epidemic (1). There have been 36 million deaths since the start of the 
epidemic and there were 35.3 million people living with HIV and 1.6 million people died 
due to AIDS worldwide in 2012 (2, 3). Sub-Saharan Africa  is home to the majority of 
those infected despite the decline in new infections over the past 10 years (2). South 
Africa in particular has one of the largest epidemics with a prevalence of 15.9% among 
adults and 16.4% among women aged between 15 and 49 years (4). Free State  
province has the third highest prevalence of HIV with 32.0% of women attending 
antenatal services in the public sector being HIV infected in 2013 (5). 
HIV can be transmitted from an HIV-infected woman to her child. The risk of vertical 
transmission can be reduced to less than 1% depending on the prophylactic regimens 
used for the mother and infant (6). 
Several study designs have been used to monitor the effectiveness of PMTCT 
programs (7). There is a lack of a standard and clear model to evaluate effectiveness of 
PMTCT programs. Measuring transmission rates alone is not sufficient as children born 
to HIV infected mothers but who do not become infected are at higher risk of morbidity 
and mortality compared to those born to uninfected mothers..  Measuring HIV-free 
survival could be a useful tool to measure effectiveness. The aim of the study was to 
determine the effectiveness of the PMTCT programs by measuring the rate of 
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transmission and HIV-free survival among children younger than 2 years of age in the 
Free State.
Methodology 
 Study design 
This study was a secondary analysis of the Free State data from a cross sectional 
survey that was conducted in 6 communities in four countries (South Africa, Cameroon, 
Zambia and Côte d'Ivoire) between November 2008 and April 2009. The South African 
study included Botshabelo, Thabo Mofutsanyana and Mantsopa sub-districts in Free 
State Province. This was a cross sectional community survey. 
The study population was all women who had given birth to a child in the previous two 
years in the catchment area of maternity facilities in three randomly selected sub 
districts in the Free Sate. Mothers were interviewed and socio-demographic information 
was collected. Blood was taken from mother and child for HIV-testing anonymously in 
the laboratory. 
Sampling method 
Study sampling was part of the original study. Multistage cluster sampling was 
employed. The catchment area for the maternity services in the three areas randomly 
selected in the Free State, were mapped. Clusters were defined from the census sub-
areas and 30 out of 210 clusters were randomly selected. A random starting point was 




until the required number of households with children born in the previous two years 
was identified, and mothers consented to be included in the study. 
Sample size  
 
We hypothesized that children exposed to PMTCT will have a higher HIV-free survival 
rate compared to those who are not. The required sample size was calculated by 
assuming 70% of children born to HIV-infected mothers would survive whereas 90% of 
children born to uninfected mothers would survive. As we wanted 80% power to detect 
this 20% difference with α=.05, we required a sample of 246 mother-infant pairs.  
Mothers (who may be dead or alive) in the household were included in the study if they 
had given birth to a child in the two years prior to the study. The study was conducted 
between November 2007 and April 2008. In cases where no one was home to 
participate in the interview, two additional attempts were made to identify an eligible 
mother in the household.  
Data collection  
 
Trained field workers interviewed mothers and collected the data under the supervision 
of trained supervisors and study coordinators. Field workers were women from the 
same communities where the study was being conducted. Interviewers were trained on 
the importance of ensuring privacy and confidentiality at all times. All identifiers were 
removed from the interview schedules once the interview was completed. The 
questionnaires were checked manually for errors during the fieldwork by supervisors 







The study questionnaire was based on several District Health Survey questionnaires 
used in different countries.  Socio-demographic and socio-economic variables were 
collected at each household. These included type of water supply, level of education, 
and antenatal and delivery care received including PMTCT service utilization. The child 
questionnaire included the type of delivery, the medications given to the mother around 
birth and weight of the infant at birth. 
Measurement  
 
Outcome measures  
 
The main outcomes were HIV-free survival and the exposures were factors associated 
with HIV transmission. All mothers of children under two years of age were asked to 
provide blood for HIV testing. The specimen collection was done only once written 
consent was obtained. All participants were advised to attend their local health clinic for 
individual HIV counselling and testing. Consenting mothers were tested using rapid HIV 
antibody tests and the children of seropositive mothers were tested using HIV DNA 
PCR tests at an external site once all identifiers had been delinked.  
Reliability and validity  
 
The questionnaire was pretested before the study was commenced in order to identify 
the validity of the tool. A pilot study was conducted to determine the feasibility and 
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acceptability of the study. A percentage of households were revisited to determine the 
reliability of data.  
 Ethical review 
All data provided for this secondary analysis was anonymised and there was no link to 
the name or address of participants. This study was approved by the University of Cape 
Town’s Faculty of Health Sciences Human Research Ethics Committee (reference 
number: HREC REF: 271/2014) (Appendix 1). 
Informed consent was obtained before a mother was accepted for the study and before 
blood was collected from a mother or child. Blood was tested in a laboratory once the 
collection of all data was complete and the name of all subjects was removed from the 
record. All test results were thus anonymous. In addition, the risk to subjects was 
minimal. Phlebotomy was conducted by a registered nurse.  The rights of the patients 
were not violated and access to health care was not affected. 
Data management and analysis 
Data from questionnaires was coded and entered on to MS Access data which was 
exported onto STATA, version 11 (StataCorp. 2009. Stata Statistical Software: Release 
11. College Station, TX: StataCorp LP.) software. Statistical tests including the chi-
squared test and Fisher’s exact test, were performed on categorical variables that were 
chosen based on clinical knowledge. Data were explored using univariate analysis to 
compute distributions and summary statistics. A bivariate analysis determined 
associations with the outcome HIV free survival. Logistic regression was used to predict 
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variables associated with HIV free survival. The log likelihood ratio and Akaike 
information criterion (AIC) were used to select the best fitting model. A p-value of <0,05 
identified statistical significance. The analysis included exposure variables such as age 
of mother, level of education attained, employment status, feeding practices, and 
whether they had received some form of PMTCT prophylaxis and the outcome variable 
was survival as well as HIV transmission. PMTCT coverage was defined as any form of 
PMTCT received, including SD NVP. Survival was compared in children exposed to 
HIV, where the mother received PMTCT and where the mother received no form of 
PMTCT and in children unexposed to HIV. The study also modelled factors associated 
with HIV transmission among children exposed to HIV.  
Results 
In the three areas where the study was conducted a total of 1158 children had been 
born in the previous two years and these mother-child pairs were eligible for the current 
study (Figure 1). Of the 1158 children under 2 years, 284 (24.5%) had missing 
information on the HIV status of the mother. This was either because the mothers 
refused to participate, agreed to participate and were interviewed but refused to provide 
HIV specimens or because the data were missing.  
The final analysis included 874 (75.50%) children. A total of 97 (11.10%) were exposed 
to HIV. Of the exposed, 21 (21.65%) were HIV positive and 76 (78.35%) were HIV 
negative and 19 (20%) were not exposed to PMTCT, 76 (80%) were exposed to 




HIV related illness. One other exposed but uninfected child died from other causes. 














Figure 1. HIV status of mothers and children under 2 years eligible for the study 
in Free State 
874 (75.50%) children had HIV status outcome 
and known exposure status 
 
97 11.10%) Exposed children 
*19 (20%) unexposed to PMTCT 
*76 (80%) exposed to PMTCT 





777 (88.90%) Unexposed children 
20 (20.62%) 
HIV positive 
and alive  
75 (77.32%) 
HIV free and 
alive  
747 (96.14) HIV free 
and alive 
30 (3.86 %) HIV-free 











1158 (100%) Children 
under 2 years old 
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Table 1 shows the characteristics of mother-child pairs. There were more male than 
female children under two years of age (53.20% and 46.80% respectively). The median 
age of the mother was 24 years (range 15 to 52 years) and 11.10% of children were 
exposed to HIV and 79.38% of HIV-infected mothers were exposed to some form of 
PMTCT. There were more mothers aged between 15 and 24 years compared to 25 to 
34 years and more women had a normal vaginal delivery than a caesarian section 
(85.98% compared to 14.08%). Table 1.1 shows the characteristics of exposed children 
included in the study. Nine children born to HIV positive mothers who were taking some 
form of antiretroviral prophylaxis (11.84%) became infected while 10 children born to 
mothers who were not taking any form of antiretroviral prophylaxis (52.63%) became 
infected. The majority of households had electricity and piped water (93.13% and 
92.45% respectively). 
Difference in survival between 2 groups of children 
Table 2.1 presents survival in exposed children stratified by exposure of the mother to 
any form of PMTCT prophylaxis. Among the children born to HIV positive mothers who 
were taking some form of antiretroviral prophylaxis, 74 (97.37%) of the 76 survived. 
Among the children who were born to HIV positive mothers who were not taking any 
form of antiretroviral prophylaxis 19 (100%) survived. There was no significant 
difference (p=0.638) in survival comparing HIV exposed children whose mothers 
received some form of  PMTCT prophylaxis compared to those who did not. Table 2.2 
shows that mothers who did not receive any form of PMTCT were 8.27 times more likely 




Factors associated with survival 
There were no significant differences in the characteristics of the mothers of children 
that survived and that did not survive (Table 3). 
Table 4 presents the characteristics of children stratified by survival. There were no 
significant differences when comparing those children who were alive and those who 
had died.  
Modelling variables associated with transmission 
Table 5 presents the characteristics of the mother and child associated with HIV 
transmission in exposed children providing both crude and adjusted measures. The 
crude model showed that mothers of HIV infected children were significantly more likely 
to be under 25 years of age, and have not received any form of PMTCT prophylaxis. 
Children who had not received any form of PMTCT prophylaxis, who had been 
hospitalised at least once since birth, and who lived in households without tapped water 
were more likely to be infected.  No variables were significantly associated with 
transmission in the adjusted multivariate analysis besides a child being hospitalized at 





1.1.  Modelling variables associated with survival 
Table 6 shows the variables associated with survival in children providing both adjusted 
and unadjusted odds ratios. In the multivariate analysis only two variables were 
significantly associated with survival. There was a 72% reduction in survival in children 
who had been hospitalised at least once since birth while those who were still breastfed 
at the time of interview were 5.08 times more likely to survive.  
Discussion 
 
This study showed that PMTCT was not associated with a reduction in HIV transmission 
in HIV-exposed children less than two years of age in the multivariate analysis and that 
the strongest predictor of survival in both exposed and unexposed children was 
exclusive breast feeding and having been admitted to hospital at least once since birth 
(8). 
Exclusive breast feeding is best practice for all children for the first six months of life and 
prior to the advent of HIV had been shown to decrease morbidity and mortality. One 
study reported that morbidity due to diarrhoea and lower respiratory tract and ear 
infections was twice as likely in children who were never breastfed (9). Although HIV is 
transmitted in breast milk, studies show a 3 to 4 fold reduction in transmission where 
children were exclusive breastfed for the first six months compared to children who 
were mixed fed.  HIV exposed children who were exclusively breastfed until 6 months of 
age had lower mortality than children who received replacement or mixed feeding in a 
study in Zimbabwe (10). Studies show that this reduction was greatest where the 
13 
mother and/or child were receiving ARV prophylaxis (10-12). Replacement feeding is 
often not feasible and may be unacceptable particularly in resource limited settings, 
hence exclusive breastfeeding is recommended.  This study showed that being 
breastfed at the time of the interview was significantly associated with survival.   
Hospitalization of children at least once since birth was associated with decreased 
survival. However it could not be ascertained whether the hospitalization was due to 
HIV infection. These finding are similar to other studies that have reported multiple 
admissions to hospital in young children who die before the age of 2 years (13). This 
may be explained by the increased risk of opportunistic infections in HIV infected 
children (14, 15).  
This study did not identify any factors associated with HIV transmission from mother to 
child. This is contrary to other studies that reported that education level attained, 
maternal age and mode of delivery were associated with HIV transmission and survival 
(16-19).  
Studies have shown that children exposed to HIV have poorer outcomes than children 
who have not been exposed. Survival rather than HIV transmission is thus a more 
appropriate way of monitoring the effectiveness of PMTCT programs. However in this 
study, there was no difference in survival in unexposed children, compared to exposed 
children irrespective of whether the mothers received some form of PMTCT or not.  The 
study was conducted in 2008 when the guidelines for PMTCT only included the use of
SD NVP which was given to the mother at the commencement of labour and to the child




current guidelines in South Africa include HAART for all pregnant women. Yet even with 
a simple intervention using SD NVP, only 80% of women received it during labour and 
74% of children received prophylaxis post-natally. This is likely to be due to losses at 
each step of the PMTCT cascade. The overall transmission rate of HIV in women who 
did not receive any form of PMTCT prophylaxis was surprisingly high (53%).  Studies 
show that in the absence of any form of intervention there is a 25–45% risk of HIV 
transmission during pregnancy, delivery or breastfeeding (20-23). Transmission from 
mothers who received PMTCT was 12%.  The HIVNET 012 RCT in Uganda (24) using 
SD NVP showed that transmission can be reduced by 47% and these results were 
corroborated by the South African Intrapartum Nevirapine Trial (SAINT) study which 
showed that giving a dose of NVP to both mother and infant during labour and after 
delivery was as effective as the HIVNET study in reducing the rate of perinatal 
transmission. Other studies have  demonstrated that MTCT can be reduced to less than 
1% in well-functioning programs (25) and best practice includes the provision of 
HAART, delivery through elective caesarian section and either exclusive breast feeding 
if a mother has been on ARVS for 3 to 6 months and has an undetectable viral load or 
replacement feeding (6, 25-28) where feasible. SD NVP is the simplest PMTCT strategy 
and although it is not the most effective, it should be the minimum intervention in 
resource-constrained settings (29, 30) or where health systems are weak (31). 
Although not significant in the adjusted analysis, vertical HIV transmission was less 
likely to occur from mothers who were 25 to 35 years of age compared to those 
between 15 and 24 years of age. This could be due to the fact that mothers in the 




Studies show that increased maternal viral load is associated with increased risk of HIV 
transmission (33).  
Studies have shown that socio-economic status is associated with vertical transmission.  
In this study electricity and tapped water in the home were used as proxy indicators for 
socio-economic status. Socio-economic status is a generic term that attempts to 
describe the underlying economic position of individuals but it is difficult to measure 
accurately in research because it encompasses many parameters. In this study these 
proxy indicators were not significantly associated with vertical transmission in the 
multivariate analysis. A study in Kenya showed that a delay in initiating PMTCT 
treatment was 1.41 times more likely for people who were unemployed and had low 
socio-economic status (36). Socio-economic status may not directly affect MTCT but 
could contribute to factors that result either in decreased access to treatment or less 
effective treatment.  
Although elective caesarian section (before the onset of labour or rupture of 
membranes) has been shown to reduce the risk of transmission of HIV by 
approximately 50% (24) caesarian section was not protective in this study. In this setting 
routine elective caesarian section is not feasible for all HIV infected women and thus it 
is not surprising that a protective effect was not seen as caesarian section was only 





This study had a number of limitations. The study may not have been sufficiently 
powered to detect factors associated with transmission and survival. During the 
multivariate analysis variables were removed due to collinearity and this also affected 
the sample size. 
Approximately 25% of mother-child pairs had missing data on HIV status. It is possible 
that mothers who refused HIV testing were more likely to be HIV infected as shown in 
household surveys in Zambia (39). This is corroborated by the fact that the prevalence 
of HIV in women in this study was lower than expected. In addition the study relied on 
participant recall and information bias such as social desirability bias may have been 
introduced.  Information about the mother and the child was provided by the guardian in 
cases where the mother had died. This may have led to further bias. 
The calculation of rates using person time would have been a more appropriate way of 
determining survival for this study. However, the date of death was not available or 
could not be verified for most of the children who died and this was a further limitation. 
Almost 25% of mothers refused to consent to participate in the study and their HIV 
status was not known. There could have been systematic differences between mothers 
who consented to be part of the study and those who did not. It was not possible to 
identify non-responders and determine if they were different to responders. Although 
data was available on breast feeding it was not clear which children had been 







This study showed breast feeding and being admitted to hospital at least once since 
birth were significantly associated with survival irrespectively of HIV exposure. PMTCT 
remains one of the most cost effective ways of combating the HIV/AIDS epidemic and 
reducing child mortality. ARV treatment is most effective when accompanied by other 
preventive methods including appropriate child feeding options and delivery by 
caesarean section. Further research should be conducted to measure the effectiveness 
of PMTCT programs by determining HIV free survival among children less than 2 years 
of age since the introduction of the new guidelines in 2010.   
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Table 1. Characteristics of mother/child pairs included in the study 
Characteristic N=874 
Sex of child   
Male 465 (53.20%) 
Female 409 (46.80) 
HIV status of the mother   
Negative 777 (88.90) 
Positive 97 (11.10) 
Age of mother   
15-24 years 455 (52.18) 
25-35 years 338 (38.76) 
Greater than 35 years 79 (9.060) Missing data n = 2 
Delivery status   
Caesarian-section 122 (14.02) 
Normal vaginal delivery 748 (85.98) Missing data n = 4 
Household has electricity   
Yes 813 (93.13) 
No 60 (6.87) Missing data n = 1 
Source of drinking water   
No tap water 29 (3.32) 
Piped water in household 808 (92.45) 
Public tap 37 (4.23) 
3 
Mother attended antenatal services at least once 
No 1 (0.11) 
Yes 870 (99.89) Missing data n = 3 
Mortality 
Living 777 (88.90) 
Not living 97 (11.10) 
Table 1.1 Characteristics of exposed children included in the study 
Characteristic  N=97 
HIV-exposed children (N=97) who received some form of PMTCT 
prophylaxis N=97 
No 22 (25.58) 
Yes 64 (74.42) Missing data n = 11 
HIV-positive mothers who received some form of PMTCT 
prophylaxis N=97 
No 19 (20.00) 
Yes 76 (80.00) Missing data n =2 
HIV transmission in HIV-exposed children  N=97 
Negative 76 (78.35) 
Positive 21 (21.65) 
4 
Table 2.1. Survival among children born to HIV-infected mothers stratified by 
exposure of the mother to some form of PMTCT, compared to unexposed 
Variable Not living living p value OR 
Mother received some form of 
PMTCT 
   No 0 (0.00%) 19 (100%) p=0.638 1.95 
Yes 2 (2.63) 74 (97.37) 
Total 2 93 
HIV and PMTCT 
HIV exposed & NOT on PMTCT  0 (0.00%)) 19 (100.00%) p=1.000 
HIV exposed & ON PMTCT 2 (6.25) 74 (97.37) 0.52 
Unexposed 30 (3.86) 747 (96.14) 8.52 
 2 children had missing information regarding PMTCT exposure from the mother
Table 2.2. HIV status of the child stratified by exposure of the mother to some 
form of PMTCT  
Variable Child HIV+ Child HIV - pvalue OR 
Mother received some 
form of PMTCT 
No 10 (52.63). 9 (47.37) P<0.001 8.27 (2.27-29.89) 
Yes 9 (11.84) 67 (97.37) 
5 
Table 3. Characteristics of mothers of children under 2 years of age stratified by 
child survival including mother’s exposure to PMTCT in HIV-exposed children 
Variable Not living (n = 32) Living (n = 842) p-value
Education level attained 
Primary 5 (4.10%) 117 (95.90 %) p=0.844 
Secondary 27 (3.80) 683 (96.20) 
Tertiary 0 (0.00) 24 (100.00) 
Age of mother 
15-24 years 13 (2.86) 442 (97.14) p=0.329 
25-35 years 15 (4.44 323 (95.56) 
Over 35 years 4 (5.06) 75 (94.94) 
Type of delivery 
Caesarian section 26 (18.31) 116 (81.69) p=0.433 
Normal vaginal delivery  6 (0.82) 722 (99.18) 
HIV status of the mother 
Negative 30 (3.86) 747 (96.14) P=0.567 
Positive 2 (2.06) 95 (97.94) 
HIV-infected mother received some 
form of  PMTCT prophylaxis (n=97) 
Not living (n = 2) Living (n = 95)  
No 0 (0.00%) 19 (100.00) p=0.638 
Yes 2 (2.63) 74 (97.37) 
Table 4. Characteristics of children under 2 years including exposure of the 
mother to PMTCT in HIV-exposed children stratified by survival. 
6 
Variable Not living (n = 32) Living(n = 842) p value 
Sex 
Male 19 (4.09%)   446 (95.91%) p=0.476 
Female 13 (3.18) 396 (96.82) 
HIV status of the child Not living (n = 2) Living (n = 95) 
Negative 1 (1.32) 75 (98.68) p=0.547  
Positive 1 (4.76) 20 (95.24) 
HIV-infected mother received some form of  
PMTCT prophylaxis (n = 97) 
No 0 (0.00) 19 (100) p=0.587 
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Sample size calculation 
Assuming: 
- Difference between children exposed to PMTCT and unexposed = 20% (p),
- 95% confidence interval (equivalent to Z2), and
- 5% precision (e):
n0 = Z2 * p * (1-p) / e2  
n0 = (1.96)2 * (0.20) * (1-0.2) /(.05)2 
n0 = 245.8624 
17 
Child questionnaire 
House Number Study Site Code 
NO QUESTIONS AND FILTERS CATEGORIES CODE SKIP
999 SECTION 10. PREGNANCY CARE 
FOR EACH CHILD. Now I would like to 
ask you some questions about the health of 
your children born in the last five years. We 
will talk about each child separately, starting 
with the most recent birth. This also 
includes any child that was born but passed 
away before it turned 2 years old in the last 
2 years. →1000
1000
1000. Record line number of [name] from 
the household listing.
Line number →1001
1001 1001. From HH listing Name living or not. Living 1 →1002
Not living 2 →1002
1002 1002. When was [name] born? Date →1003
1003 1003. Are you [name's] biologic mother? Yes 1 →1004
No 2 →1100
1004 1004. When you were pregnant with 





1005 I005. Is there any antenatal record or 
consultation book for [name] where 




1006 1006. May I see it? (if reluctant response, 
encourage to view booklet)
Yes 1 →1007
No 2
I can not find booklet at the 
moment
3
1007 1007. Where did you first receive antenatal 
care?
Home ("unbooked") 1 →1010
Govt Hosp 2 →1008
Govt Health Centre 3
Govt Health Post 4
Private sector Clinic 5
Mission Hospital 6
Mission Health Centre 7
Mission Health Post (primary 
health center) 8
Other 9
1008 1008. Please tick source of information . Only Recall 1 →1009
Only Medical record 2
Medical record and Recall 3
Other 4
1009 1009. Name of Health Facility (fill out 




1010 1010. Please tick source of information. Only Recall 1 →1011
Only Medical record 2
Medical record and Recall 3
Other 4
1011 1011. During [name's] pregnancy how many 
months pregnant were you when you first 
received antenatal care?









1012 1012. Please tick source of information . Only Recall 1 →1013
Only Medical record 2
Medical record and Recall 3
Other 4




Don't know 3 →1017
1014 1014. Please tick source of information . Only Recall 1 →1015
Only Medical record 2
Medical record and Recall 3
Other 4




1016 1016. Please tick source of information. Only Recall 1 →1017
Only Medical record 2
Medical record and Recall 3
Other 4
1017 1017. During [name's] pregnancy what was 
the result of your syphilis test?
Positive 1 →1018
Negative 2
Don't want to tell you 3 →1019
Don't know 4
1018 1018. Please tick source of information. Only Recall 1 →1019
Only Medical record 2
Medical record and Recall 3
Other 4






1020 1020. Please tick source of information. Only Recall 1 →1021
Only Medical record 2
Medical Record and Recall 3
Other 4




Don't know 3 →1025
Don't want to tell you 4 →1100
1022 1022. Please tick source of information. Only Recall 1 →1023
Only Medical record 2
Medical Record and Recall 3
Other 4
1023 1023. What was the result of this test? HIV positive 1 →1024
HIV negative 2
Don't know 3 →1025
Don't want to tell you 4 →1200
1024 1024. Please tick source of information. Only Recall 1 →1025
Only Medical record 2
Medical Record and Recall 3
Other 4
1025 1025. During (Name's) pregnancy, were 
you given any drugs to prevent mother to 




No, I am already taking HAART 3 →1035
No, I tested HIV negative 4 →1200
Can not remember 5
1026 1026. Please tick source of information. Only Recall 1 →1027
Only Medical record 2
Medical Record and Recall 3
Other 4
1027 1027. What medications were you given? 
(show pictures to help remember)
NVP only 1 →1028
AZT only 2
NVP and AZT 3
HAART (or local name) 4 →1035
Can not remember 6 →1200
Other 7 →1200
1028 1028. Please tick source of information. Only Recall 1 →1029
Only Medical record 2
Medical Record and Recall 3
Other 4
1029 1029. Did you take the Nevirapine tablet? Yes 1 →1030
No 2 →1034
Can not remember 3 →1032
20 
1030 1030. When did you take the Nevirapine 
tablet?
When I went into labor 1 →1031
After I delivered 2
1-7 days before delivery 3
Can not remember 4 →1034
1031 1031. How many times did you take the 
Nevirapine tab?
One time 1 →1034
Two times 2
More than 2 times 3
Can not remember 4
1032 1032. Did you take the AZT? Yes 1 →1033
No 2 →1200
I was not given AZT tablets 3
Can not remember 4
1033 1033. If you were given AZT, how many 
tablets did you take?
All of the tablets 1 →1034
Some Of The Tablets 2
None of the tablets 3 →1200
Can not remember 4
1034 1034. During [Name's] pregnancy, when 
did you start taking the AZT tablets?









Can not remember 10
1035 1035. When did you start taking HAART? Before pregnancy 1 →1200
During pregnancy 2
After delivery 3
Can not remember 4
NO QUESTIONS AND FILTERS CATEGORIES CODE SKIP
1100 SECTION 11: QUESTIONS FOR 
CAREGIVER OTHER THAN MOTHER
Continue 1 →1101
back to index 2 →31
1101 1101. What is reason that [name] is not 
staying with the mother?
Mother has passed away 1 →1102
Mother lives elsewhere 2 →1102
1102 1102. Did the mother consult for antental 
care in this pregnancy?
Yes 1 →1103
No 2 →1200
Don’t Know 3 →1200
1103 1103. Where did her first ANC visit take 
place? (fill in 'unknown' if unknown)
Place text →1104
1104 1104. Name of Health Facility Name text →1105
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1105 1105. How many months pregnant was she 
when she first received antenatal care?










NO QUESTIONS AND FILTERS CATEGORIES CODE SKIP
1200 SECTION 12: REVIEW OF ANTENATAL 




Back to index 2
→32
1201 1201. Do you have the ANC card from this 
pregancy? If so, can it be shown? (verfiy Q 
1202-1204)
Yes, Seen 1 →1202
Yes, Not Seen 2 →1300
No Card 3 →1300




Nothing written on card 5
1203 1203. Syphilis test result Pos 1 →1204
Neg 2
Not done 3
Nothing written on card 4
1204 1204. Hemoglobin (fill out '00' if unknown)
Grams 
text →1300
NO QUESTIONS AND FILTERS CATEGORIES CODE
1300
SECTION 13: BIRTH HISTORY FOR 
EACH CHILD (if biological mother has passed 
away ask a reliable family member)
Continue 1
→1301
Back to index 2
→33
1301 1301. Where did the birth of [name] take 
place?
Your Home 1 →1302
Other Home 2
Govt Hospital 3 →1303
Govt Health Clinic 4
Govt Health Post 5
Private Hospital/Clinic 6
Mission Hospital 7
Mission Health Clinic 8
Mission Health Post (primary 
health center)
9
Don't know 10 →1304
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1302 1302. Was [name] taken to a health center 





















HEALTH PROFESSIONAL : 











1306 1306. Was [name] weighed at birth? Yes 1 →1307
No 2 →1308
Don't know/not recorded 9
1307 1307. How much did [name] weigh? (fill out 
'00' if unknown) grams
→1308
1308 1308. Did [name] receive any Polio 




Do not remember/Do not know 3
1309 1309. Did [name] receive any AZT syrup in 




Do not remember/Do not know 3
Not applicable (mother HIVneg) 4 →1312
1310 1310. Did [name] receive any Nevirapine 
syrup in his mouth before discharge from 
the clinic or hospital?
Yes 1 →1311
No 2
Do not remember 3
Not applicable (mother HIVneg 
)
4
1311 1311. Was [name] given Bactrim/Cozole to 
take every day beginning at 6 weeks even 
when [name] was not sick?
Yes 1 → 1312
No 2
Do not know 3
1312 1312. Was [name] ever breastfed? Yes 1 →1313
No 2 →1315
1313 1313. Is [name] still breastfeeding? (ONLY Yes 1 →1315
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ASK IF CHILD STILL LIVING) No 2 →1314
24 
1314 1314. For how many months was [name] 
breastfed?











Longer than 2 years 12
1315 1315. How old was [name] when you first 
gave him/her water?
0-7 Days after birth 1 →1316
2-4 Weeks after birth 2
1-2 Months after birth 3
3-4 Months after birth 4
5-6 Months after birth 5
More than 6 months after birth 6
Child was never given water 7
Do not remember 8
1316 1316. Was [name] ever given formula? 
(Note: formula is a specially prepared 




Do not know 9
1317 1317. How old was [name] when formula 
was given for the first time? (fill in 1/1/2010 
if unknown)
Date →1318
1318 1318. Why was [name] given formula 
feeding? (circle all that apply) (Note: formula is 
a specially prepared commercial product/food 
for babies like Pelargon/NAN/SMA)
Mother too sick to breast feed 1 →1319
Mother died 2
Mother didn't have enough milk 3
[Name] was not staying with the 
mother
4
To prevent HIV transmission 5
Thought it was good for [name] 6




Do not know/Do not remember 9
1319 1319. Has [name] ever had tinned, 
powdered or fresh animal milk?
Yes 1 →1320
No 2 →1322
Do not know/Do not remember 3
25 
1320 1320. How old was [name] when milk such 
as tinned, powdered or fresh animal milk 
was given for the first time? (fill in '1/1/2010' 
if unknown)
Date →1321
1321 1321. Why was [name] given milk? (circle 
all that apply)
Mother too sick to feed 1 →1322
Mother died 2
Mother did not produce enough 
milk
3
Baby was not staying with the 
mother
4
To prevent HIV transmission 5
Thought it was good for the 
child
6





Do not know/Do not remember 9




Do not know/Do not remember 3
1323 1323. How old was [name] when tea, coffee 
or juice were given for the first time?
0-2 Months 1 →1324





More than 12 months
6
Can not remember 7
1324 1324. Has [name] ever been given porridge 
or semi solid food?
Yes 1 →1325
No 2 →1326
Do not know/Do not remember
9
1325 1325. How old was [name] when porridge 
or other semi solid food were given to him?
0-2 Months 1 →1326




More than 12 months 6
Can not remember 7






Do not know/Do not remember
3
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1327 1327. How old was [name] when family 








More than 12 months 6
Can not remember 7
1328 1328. What did [name] eat and drink 
yesterday? (Mark all that apply)








1329 1329. Did anyone at the health facility 
instruct you on how to feed your infant 
after you were discharged or when you 
came for Post Natal Care?
Yes 1 →1330
No 2
1330 1330. Has [name] been tested for HIV? Yes 1 →1331
No 2 →1332
1331 1331. When was [name] tested for HIV? 
(fill in '1/1/2010' if unknown)
Date →1332





Do not want to tell you 5
1333 1333. Has [name] ever spent the night in a 




Do not know/Do not remember 9
1334 1334. How many times has [name] been 
hospitalized?
1 Time hospitalized 1 →1335
2 Times hospitalized 2
3 Times hospitalized 3
4 Times hospitalized 4
More than 4 times hospitalized 5
Do not know 6












NO QUESTIONS AND FILTERS CATEGORIES CODE SKIP
1400 SECTION 14: CHILD HEALTH CARD
Continue 1 →1401
Back to index 2 →34
1401 1401. Do you have an under 5 card where 
[name's] vaccinations are written down? If 
Yes, may I please see it?
Yes, Seen 1 →1402
Yes, Not Seen 2
No Card
3
1402 1402. BCG Yes 1 →1403
No 2
1403 1403. Date BCG: (fill out '1/1/2010' if 
unknown) Date: 
→1404
1404 1404. OPV0 Yes 1 →1405
No 2
1405 1405. Date OPV0: (fill out '1/1/2010' if 
unknown) Date: 
→1406
1406 1406. OPV1 Yes 1 →1407
No 2
1407 1407. Date OPV1: (fill out '1/1/2010' if 
unknown)
Date: →1408
1408 1408. OPV2 Yes 1 →1409
No 2
1409 1409. Date OPV2: (fill out '1/1/2010' if 
unknown)
Date: →1410
1410 1410. OPV3 Yes 1 →14011
No 2
1411 1411. Date OPV3: (fill out '1/1/2010' if 
unknown)
Date: →1412
1412 1412. DPT1 Yes 1 →14013
No 2




1414 1414. DPT2 Yes 1 →1415
No 2
1415 1415. Date DTP2: (fill out '1/1/2010' if 
unknown)
Date: →1416
1416 1416. DPT3 Yes 1 →1417
No 2
1417 1417. Date DTP3: (fill out '1/1/2010' if 
unknown)
Date: →1418
1418 1418. Measles Yes 1 →1419
No 2




1420 1420. Vitamin A Yes 1 →1421
No 2
1421 1421. Date Vitamin A: (fill out '1/1/2010' if 
unknown)
Date: →1422
1422 1422. IF CARD IS AVAILABLE: Is there an 




1423 1423. Is there any indication that [name] 
received PMTCT? (Check all that apply)
Mother’s HIV status noted 1 →1414
NVP given to mother 2
NVP given to [name] 3
AZT given to mother 4
AZT given to [name] 5
HAART given to mother 6
Other 7
No 8
1424 1424. Is [name's] HIV test result on card? Yes 1 → 1425
No 2 → 1426
1425 1425. Is [name] HIV infected? Yes 1 → 1426
No 2




1426 1426. Do you have more children below the 
age of 5 years living in this house? (refer to 
children biological mother)
Yes 1 → 1000
No 2 → 1500
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House Number Study Site Code 
NO QUESTIONS AND FILTERS CATEGORIES CODE SKIP
1500 1500. SECTION 15  PHYSICAL 
EXAM/LAB TESTS. Enter Line number 
mother (drop down list)
Line number →1501
1501 1501. Was Mother's Height (cm) (record to 
nearest 0.5 cm) recorded?
Yes, Height of the mother was recorded 1 →1502
No, Height of the mother was not recorded 2 →1503
1502 1502. What was the Height of the mother? Height in cm →1504
1503 1503. The Height of the Mother was not 
collected. Reason:
Equipment did not work 1 →1504
Equipment was not complete 2
Mother has physical handicap, which makes 
measurment not possible
3
Refusal during informed consent 4
Refused after informed consent was approved 5
Other 6
1504 1504. Was Mother's Weight (kg) (record 
digital read out) collected?
Yes, Weight of the mother was recorded 1 →1505
No, Weight of the mother was not recorded 2 →1506
1505 1505. What was the Weight of the mother? Weight in kg →1507
1506 1506. The Weight of the Mother was not 
collected. Reason:
Equipment did not work 1 →1507
Equipment was not complete 2
Child has physical handicap, which makes 
measurment not possible
3
Refusal during informed consent 4
Refused after informed consent was approved
5
Other 6
1507 1507. Was Mother's Blood Obtained? Yes 1 →1509
No 2 →1508
1508 1508. The blood sample was not collected 
from the mother. Reason:
Refusal during the Informed Consent 1 →1509
Mother changed her mind after Informed 
Consent approval
2
Could not find a vein 3
Other 4










Not possible to do test, because could not be 
collected
4
1511 1511. Was an Oraquick swab obtained from 
the mother?
Yes 1 →1512
No, blood sample already collected 2
No, refusal during informed consent 3
No, refused after approval informed consent 4
No, test not done in country 5
1512 1512. Enter line number Child Line number →1513
1513 1513. Was the Height of [Child Name's] 
recorded?
Yes, Height of the child was recorded 1 →1514
No, Height of the child was not recorded 2 →1515
1514 1514. What was the Height of the child? Height in cm: →1516
1515 1515. The Height of [Child Name] was not 
recorded. Reason:
Equipment did not work 1 →1516
Equipment was not complete 2
Child was so upset, it could not be measured 
properly
3
Child has physical handicap, which makes 
measurment not possible
4
Refusal during informed consent
5




1516 1516. Was the Weight of [Child Name] 
recorded? (in kg to nearest 0.1 kg)
Yes, the Weight of the child was recorded 1 →1517
No, the Weight of the child was not recorded 2 →1518
1517 1517. What was the Weight of the child? Weight in kg; →1519
1518 1518. The Weight of [Child Name] was not 
recorded. Reason:
Equipment did not work
1 →1519
Equipment was not complete
2
Child was so upset, it could not be measured 
properly
3
Child has physical handicap, which makes 
measurment not possible
4
Refused after informed consent was approved
5





1519 1519. Was an antibody test performed on 
this child? 









Bioline HIV1 positive 5





Not appplicable/other country than Cameroon
10
1520 1520. Was [Child Name's] Blood Obtained 
on a Dried Blood Spot Card?
Yes 1 →1522
No 2 →1521
1521 1521. The Blood was not obtained on the 
Dried Blood Spot Card of [Child Name]. 
Reason:
Equipment did not work
1 →1522
Equipment was not complete
2
Child was so upset, it could not be measured 
properly
3
Child has physical handicap, which makes 
measurment not possible
4
Refusal during informed consent 5
Refused after informed consent was approved 6
Other
7
1522 1522. Was [Child Name's] Hemoglobin 




1523 1523. What was the result of the 
Hemoglobin test?
Result  --.-- g/dl →1525
1524 1524. The Hemoglobin result was not 
collected. Reason:
Equipment did not work 1 →1525
Equipment was not complete
2
Child was so upset, it could not be measured 
properly
3
Child has physical handicap, which makes 
measurment not possible
4
Refused after informed consent was approved
5
Other 6
1525 1525. Any other children from this biological 
mother, that are below 5 years and were 
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journal's web site at http://pidj.edmgr.com/. See submission instructions under "Online 
manuscript submission." 
Patient anonymity and informed consent: It is the author's responsibility to ensure that a 
patient's anonymity be carefully protected and to verify that any experimental investigation with 
human subjects reported in the manuscript was performed with informed consent and following all 
the guidelines for experimental investigation with human subjects required by the institution(s) 
with which all the authors are affiliated. Authors should mask patients' eyes or, if the eye area is 
the focus of the illustration, the patient's nose and mouth, and they should remove patients' 
names from figures unless written consent obtained from the patients is submitted with the 
manuscript. 
Copyright: The corresponding author will complete the copyright questions within the submission 
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which they will verify their co-authorship and complete the Copyright Transfer and Disclosure Form 
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Methods, Results, and Conclusions (others may be added as needed). 
Unstructured abstract for Instructive Cases and Brief Reports: Abstract must be submitted 
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use of abbreviations and acronyms, and avoid general statements (e.g. "the significance of the 
results is discussed"). 
Brief Reports: Papers for this section should be no longer than 5-6 double-spaced typed 
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not include Title Page or Unstructured Abstract. 
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should contain 500 words or fewer and less than 5 references. 
ESPID Reviews and Reports: ERR reviews should contain a maximum of 2000 words (including 
references) and include up to 10 references and 1 table or figure. There is no abstract. A 
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Results, and Discussion. If a brand name is cited, supply the manufacturer's name and address 
(city and state/country). 
Abbreviations: For a list of standard abbreviations, consult the American Medical Association 
Manual of Style, 9th edition, or other standard sources. Write out the full term for each 
abbreviation at its first use unless it is a standard unit of measure. Abbreviations are allowed only 
if used three times or more in text. 
References: The authors are responsible for the accuracy of the references. Key the references 
(double-spaced) at the end of the manuscript. Cite the references in text in the order of 
appearance, including those references cited in tables and figure legends at the chronological 
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A) Creating Digital Artwork
1. Learn about the publication requirements for Digital Artwork: http://links.lww.com/ES/A42
2. Create, Scan and Save your artwork and compare your final figure to the Digital Artwork
Guideline Checklist (below).
3. Upload each figure to Editorial Manager in conjunction with your manuscript text and
tables.
B) Digital Artwork Guideline Checklist
Here are the basics to have in place before submitting your digital artwork: 
 Artwork should be saved as TIFF, EPS, or MS Office (DOC, PPT, XLS) files. High resolution
PDF files are also acceptable.
 Crop out any white or black space surrounding the image.
 Diagrams, drawings, graphs, and other line art must be vector or saved at a resolution of
at least 1200 dpi. If created in an MS Office program, send the native (DOC, PPT, XLS) file.
 Photographs, radiographs and other halftone images must be saved at a resolution of at
least 300 dpi.
 Photographs and radiographs with text must be saved as postscript or at a resolution of at
least 600 dpi.
 Each figure must be saved and submitted as a separate file. Figures should not be
embedded in the manuscript text file.
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 Cite figures consecutively in your manuscript.
 Number figures in the figure legend in the order in which they are discussed.
 Upload figures consecutively to the Editorial Manager web site and enter figure numbers
consecutively in the Description field when uploading the files.
Figure legends: Include legends for all figures. They should be brief and specific, and they should 
appear on a separate manuscript page after the references. Legends should be part of the 
manuscript file on the disk. Use scale markers in the image for electron micrographs, and indicate 
the type of stain used. 
Color figures: The journal accepts for publication color figures that enhance an article. Authors 
who submit color figures receive an estimate of the cost for color reproduction. If they decide not 
to pay for color reproduction, they can request that the figures be converted to black and white at 
no charge. 
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journals that enhance their article's text to be considered for online posting. SDC may include 
standard media such as text documents, graphs, audio, video, etc. On the Attach Files page of the 
submission process, please select Supplemental Audio, Video, or Data for your uploaded file as the 
Submission Item. All SDC files should be uploaded as the author would like them presented in the 
final article. If an article with SDC is accepted, our production staff will create a URL with the SDC 
file. The URL will be placed in the call-out within the article. SDC files are not copyedited by LWW 
staff, they will be presented digitally as submitted. For SDC documents, any labels or legends 
should be included in the original SDC file when submitted. For a list of all available file types and 
detailed instructions, please visit http://links.lww.com/A142. 
SDC Call-outs 
Supplemental Digital Content must be cited consecutively in the text of the submitted manuscript. 
Citations should include the type of material submitted (Audio, Figure, Table, etc.), be clearly 
labeled as "Supplemental Digital Content," include the sequential list number, and provide a 
description of the supplemental content. All descriptive text should be included in the call-out as it 
will not appear elsewhere in the article.  
Example:  
We performed many tests on the degrees of flexibility in the elbow (see Video, Supplemental 
Digital Content 1, which demonstrates elbow flexibility) and found our results inconclusive. 
List of Supplemental Digital Content 
A listing of Supplemental Digital Content must be submitted at the end of the manuscript file. 
Include the SDC number and file type of the Supplemental Digital Content. This text will be 
removed by our production staff and not be published. 
Example: 
Supplemental Digital Content 1. wmv 
SDC File Requirements 
All acceptable file types are permissible up to 10 MBs. For audio or video files greater than 10 MBs, 
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authors should first query the journal office for approval. For a list of all available file types and 
detailed instructions, please visit http://links.lww.com/A142. 
Tables: Create tables using the table creating and editing feature of your word processing 
software (e.g., Word, WordPerfect). Do not use Excel or comparable spreadsheet programs. 
Provide a separate document for each table. Cite tables consecutively in the text, and number 
them in that order. Key each on a separate sheet, and include the table title, appropriate column 
heads, and explanatory legends (including definitions of any abbreviation not already defined in 
the text). Do not embed tables within the body of the manuscript. They should be self-explanatory 
and should supplement, rather than duplicate, the material in the text. In each table, the genus of 
each genus-species must be written out at its first appearance. 
Style: Stedman's Medical Dictionary (27th edition) and Merriam Webster's Collegiate 
Dictionary (10th edition) should be used as standard references. Refer to drugs and therapeutic 
agents by their accepted generic or chemical names, and do not abbreviate them. Use code 
numbers only when a generic name is not yet available. Capitalize the trade names of drugs and 
place them in parentheses after the generic names. To comply with trademark law, include the 
name and location (city and state/country) of the manufacturer of any drug, supply, or equipment 
mentioned in the manuscript. Use the metric system to express units of measure and degrees 
Celsius or degrees Fahrenheit consistently throughout the manuscript to express temperatures, 
and use SI units rather than conventional units. Abbreviate "liter" in such forms as "3 units/L" and 
"5 mL"; write out when used alone (10 liters; 0.5-liter gavage). See also Day RA, ed. How to Write 
and Publish a Scientific Paper. 5th ed. Phoenix, AZ: The Oryx Press, 1998. 
Financial disclosure: In the cover letter, indicate all affiliations with or financial involvement in 
any organization or entity with a direct financial interest in the subject matter or materials of the 
research discussed in the manuscript (e.g. employment, consultancies, stock ownership). All such 
information will be held in confidence during the review process. Should the manuscript be 
accepted, the Chief Editors will discuss with the author the extent of disclosure appropriate for 
publication. 
After Acceptance  
Open access  
LWW’s hybrid open access option is offered to authors whose articles have been accepted for 
publication. With this choice, articles are made freely available online immediately upon 
publication. Authors may take advantage of the open access option at the point of acceptance to 
ensure that this choice has no influence on the peer review and acceptance process. These articles 
are subject to the journal’s standard peer-review process and will be accepted or rejected based 
on their own merit. 
Authors of accepted peer-reviewed articles have the choice to pay a fee to allow perpetual 
unrestricted online access to their published article to readers globally, immediately upon 
publication. The article processing charge for The Pediatric Infectious Disease Journal is $3,100. 
The article processing charge for authors funded by the Research Councils UK (RCUK) is $3,900. 
The publication fee is charged on acceptance of the article and should be paid within 30 days by 
credit card by the author, funding agency or institution. Payment must be received in full for the 
article to be published open access. 
Authors retain copyright: Authors retain their copyright for all articles they opt to publish open 
access. Authors grant LWW a license to publish the article and identify itself as the original 
publisher. 
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Creative Commons license: Articles opting for open access will be freely available to read, 
download and share from the time of publication. Articles are published under the terms of the 
Creative Commons License Attribution-NonCommerical No Derivative 3.0 which allows readers to 
disseminate and reuse the article, as well as share and reuse of the scientific material. It does not 
permit commercial exploitation or the creation of derivative works without specific permission. To 
view a copy of this license visit:http://creativecommons.org/licenses/by-nc-nd/3.0. 
Compliance with NIH, RCUK and other research funding agency accessibility 
requirements: A number of research funding agencies now require or request authors to submit 
the post-print (the article after peer review and acceptance but not the final published article) to a 
repository that is accessible online by all without charge. As a service to our authors, LWW 
identifies to the National Library of Medicine (NLM) articles that require deposit and transmits the 
post-print of an article based on research funded in whole or in part by the National Institutes of 
Health, Howard Hughes Medical Institute, or other funding agencies to PubMed Central. The 
revised Copyright Transfer Agreement provides the mechanism. LWW ensures that authors can 
fully comply with the public access requirements of major funding bodies worldwide. Additionally, 
all authors who choose the open access option will have their final published article deposited into 
PubMed Central. 
RCUK funded authors can choose to publish their paper as open access with the payment of an 
article process charge, or opt for their accepted manuscript to be deposited (green route) into PMC 
with an embargo. 
With both the gold and green open access options, the author will continue to sign the Copyright 
Transfer Agreement (CTA) as it provides the mechanism for LWW to ensure that the author is fully 
compliant with the requirements. After signature of the CTA, the author will then sign a License to 
Publish where they will then own the copyright. 
It is the responsibility of the author to inform the Editorial Office and/or LWW that they have RCUK 
funding. LWW will not be held responsible for retroactive deposits to PMC if the author has not 
completed the proper forms. 
FAQ for open access: http://links.lww.com/LWW-ES/A48 
Page proofs and corrections: Corresponding authors receive page proofs to check the 
copyedited and typeset article before publication. Portable document format (PDF) files of the 
typeset pages and support documents (e.g., reprint order form) are sent to the corresponding 
author by E-mail. Complete instructions are provided with the E-mail for downloading and printing 
the files and for faxing the corrected page proofs to the publisher. Those authors without an E-mail 
address receive traditional page proofs. It is the author's responsibility to ensure that there are no 
errors in the proofs. Changes that have been made to conform to journal style stand if they do not 
alter the authors' meaning. Only the most critical changes to the accuracy of the content are 
made. Changes that are stylistic or are a reworking of previously accepted material are disallowed. 
The publisher reserves the right to deny any changes that do not affect the accuracy of the 
content. Authors may be charged for alterations to the proofs beyond those required to correct 
errors or to answer queries. Proofs must be checked carefully and returned within 24 to 48 hours 
of receipt, as requested in the cover letter accompanying the page proofs. 
Reprints: Authors receive a reprint order form with the page proofs that includes reprint costs. 
Reprint order forms should be returned to Author Reprint Department, Lippincott Williams & 
Wilkins, 351 West Camden Street, Baltimore, MD 21201-2436. Reprints are normally shipped 6 to 
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8 weeks after publication of the issue in which the item appears. Contact the Author Reprint 
Department, Lippincott Williams & Wilkins, 351 W. Camden Street, Baltimore, MD 21201; Fax: 
410-528-4434; E-mail: reprintsgroup@lww.com with any questions.
Permissions: For permission and/or rights to use content for which the copyright holder is LWW 
or the society, please go to the journal's website and after clicking on the relevant article, click on 
the "Request Permissions" link under the "Article Tools" box that appears on the right side of the 
page. Alternatively, send an e-mail tocustomercare@copyright.com. 
For Translation Rights & Licensing queries, contact Silvia Serra, Translations Rights, Licensing & 
Permissions Manager, Wolters Kluwer Health (Medical Research) Ltd, 250 Waterloo Road, London 
SE1 8RD, UK. Phone: +44 (0) 207 981 0600. E-mail: silvia.serra@wolterskluwer.com 
For Special Projects and Reprints (U.S./Canada), contact Alan Moore, Director of Sales, Lippincott 
Williams & Wilkins, Two Commerce Square, 2001 Market Street, Philadelphia, PA 19103. Phone: 
215-521-8638. E-mail: alan.moore@wolterskluwer.com
For Special Projects and Reprints (non-U.S./Canada), contact Silvia Serra, Translations Rights, 
Licensing & Permissions Manager, Wolters Kluwer Health (Medical Research) Ltd, 250 Waterloo 
Road, London SE1 8RD, UK. Phone: +44 (0) 207 981 0600. E-
mail: silvia.serra@wolterskluwer.com 
Publisher's contact: Send corrected page proofs, color letters, and any other related materials to 
Emily Weisenreder, Emily.Weisenreder@wolterskluwer.com, 410-528-4102 (phone), 443-451-
8147 (fax), or mail to Emily Weisenreder, Wolters Kluwer Health, 351 W. Camden Street, 
Baltimore, MD 21201. 
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